Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPA.0000000000002202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sjögren's syndrome positive for isolated anti-Ro52/SS-A antibody and anti-centromere antibody.
J Int Med Res
November 2024
Division of Human Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
This current case report describes a Japanese woman in her 80s with xerostomia who presented with salivary gland dysfunction. She was positive for isolated anti-Ro52/SS-A antibody as determined by a chemiluminescent enzyme immunoassay and positive on a fluorescence enzyme immunoassay that recognizes both Ro52 and Ro60 antigens. A high serum concentration of anti-Ro52/SS-A antibody was determined by an enzyme-linked immunosorbent assay.
View Article and Find Full Text PDFEvidence that autoantibody production may be driven by acute Epstein-Barr virus infection in Sjögren's disease.
Ann Rheum Dis
October 2024
Division of Rheumatology and Clinical Immunology, University of Florida Health Science Center, Gainesville, Florida, USA
Article Synopsis
- - Sjögren's disease (SD) is an autoimmune condition linked to specific autoantibodies, and a case study showed that a previously healthy individual developed SD after primary Epstein-Barr virus (EBV) infection, resulting in multiple autoantibody productions.
- - Researchers examined immune responses to various autoantigens and found that anti-Ro52 and anti-Ro60 autoantibodies started to appear shortly after EBV infection, with levels continuing to rise alongside other antibodies long after the initial infection.
- - The study concludes that EBV infection can trigger specific autoantibody responses through different mechanisms, and it notes that some healthy individuals can produce certain autoantibodies independently of the EBV response.
Impact of IgG Fc Glycosylation on Disease Dynamics in Patients With Primary Sjögren Disease.
Arthritis Rheumatol
September 2024
Ghent University Hospital and Gent University, Ghent, Belgium, VIB-UGent Inflammation Research Center, Zwijnaarde, Belgium, and AZ Sint-Jan Brugge AV, Bruges, Belgium.
Article Synopsis
- The study investigates how glycan modifications on IgG antibodies affect their role in inflammation, focusing on patients with primary Sjögren disease (SjD).
- Researchers analyzed IgG glycosylation in 300 patients, finding lower levels of sialylation and galactosylation in those with SjD compared to asymptomatic individuals; these changes correlate with increased B cell activation and various autoantibody profiles.
- The findings suggest that IgG Fc glycosylation could serve as a new marker for predicting disease progression, monitoring activity, and assessing lymphoma risk in SjD patients.
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus.
Rheumatology (Oxford)
August 2024
Department of Rheumatology, Monash Health, Clayton VIC 3168, Australia.
Objectives: Anti-Ro60 and anti-Ro52 autoantibodies are frequently used as diagnostic biomarkers for Sjogren's disease, but their clinical significance in systemic lupus erythematosus (SLE) is not well characterised.
Methods: Patients fulfilling SLE classification criteria were studied according to their anti-Ro status. We defined Ro positivity (Ro+) as those who have either anti-Ro60 or anti-Ro52 positivity.
Should Physicians Be Aware of Rhythm Disturbances in Adults with Systemic Autoimmune Diseases and Anti-Ro52 Antibodies? A Cross-Sectional Study.
J Clin Med
June 2024
Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud de Castilla y León (SACYL), Avda. Ramón y Cajal nº3, 47003 Valladolid, Spain.
The association between anti-Ro/SSA antibodies and the appearance of cardiac rhythm disorders in adults is discussed. We aim to study this relationship, together with active treatments and comorbidities, and its impact on daily clinical practice in adults with systemic autoimmune diseases (SADs). This cross-sectional single-center study was conducted in a tertiary hospital between January 2021 and March 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!